Skip to content
Evigrade
CriticalOxazolidinone antibiotic×Atypical antipsychotic – indole derivative

Updated · Methodology

Mechanism

Linezolid is an antibiotic that reversibly and non-selectively inhibits monoamine oxidase, so it is itself a monoamine oxidase inhibitor (MAOI), although it has no antidepressant effect at antibacterial doses (linezolid summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Ziprasidone blocks dopamine and serotonin receptors, and it is also a potent agonist at 5-HT1A serotonin receptors and inhibits the reuptake of serotonin and noradrenaline (ziprasidone SmPC, AEMPS). According to the US label, ziprasidone can precipitate potentially life-threatening serotonin syndrome, and the risk rises with drugs that impair the metabolism of serotonin, that is, MAOIs (ziprasidone label, US Food and Drug Administration, FDA). The two drugs do not interact through liver enzymes: cytochrome P450 (CYP) enzymes do not metabolise linezolid to any detectable extent, and linezolid does not inhibit them (linezolid SmPC, AEMPS). About two-thirds of ziprasidone is cleared through reduction by glutathione and the enzyme aldehyde oxidase, and less than one-third through CYP enzymes (ziprasidone label, FDA).

Symptoms

Serotonin syndrome presents with mental status changes (agitation, hallucinations, delirium, coma), autonomic instability (fast heart rate, labile blood pressure, dizziness, sweating, flushing, high body temperature), neuromuscular symptoms (tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, nausea, vomiting and diarrhoea (ziprasidone label, US Food and Drug Administration, FDA). The Spanish ziprasidone summary of product characteristics (SmPC) reports isolated cases of serotonin syndrome when ziprasidone was combined with other serotonergic drugs, such as selective serotonin reuptake inhibitors. It lists confusion, agitation, fever, sweating, ataxia, hyperreflexia, myoclonus and diarrhoea among the features (ziprasidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). When the combination with linezolid cannot be avoided, watch for cognitive dysfunction, very high fever, hyperreflexia and incoordination (linezolid SmPC, AEMPS).

Management

The US ziprasidone label contraindicates the combination. Ziprasidone must not be taken with monoamine oxidase inhibitors (MAOIs), including linezolid, or within 14 days of stopping them, and must not be started in a patient being treated with linezolid (ziprasidone label, US Food and Drug Administration, FDA). If a patient taking ziprasidone needs linezolid, stop ziprasidone before starting linezolid (ziprasidone label, FDA). The Spanish ziprasidone summary of product characteristics (SmPC) does not mention MAOIs (ziprasidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish linezolid SmPC contraindicates linezolid with serotonergic agents unless the combination is absolutely necessary (linezolid SmPC, AEMPS). In that case, watch the patient closely for signs of serotonin syndrome and, if they appear, consider stopping one or both drugs (linezolid SmPC, AEMPS). In serotonin syndrome, stop ziprasidone and any other serotonergic drugs at once and start supportive treatment (ziprasidone label, FDA). After a course of linezolid, wait at least 14 days before starting ziprasidone (ziprasidone label, FDA). No document gives an interval between stopping ziprasidone and starting linezolid. The mean terminal half-life of oral ziprasidone is 6.6 hours (ziprasidone SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Linezolid

Other interactions with Ziprasidone